Abstract: The I (f) channel inhibitor ivabradine is recommended for treatment of heart failure but also affects potassium currents and thereby prolongs ventricular repolarization. The aim of this study was to examine the electrophysiological effects of ivabradine on digitalis-induced ventricular arrhythmias.Thirteen rabbit hearts were isolated and Langendorff-perfused. After obtaining baseline data, the digitalis glycoside ouabain was infused (0.2 lM). Monophasic action potentials and ECG showed a significant abbreviation of QT interval (À34 ms, p < 0.05) and action potential duration (APD 90 ; À27 ms, p < 0.05). The shortening of ventricular repolarization was accompanied by a reduction in effective refractory period (ERP; À27 ms, p < 0.05). Thereafter, hearts were additionally treated with ivabradine (5 lM). Of note, this did not exert significant effects on QT interval (À4 ms, p = ns) or APD 90 (À15 ms, p = ns) but resulted in an increase in ERP (+17 ms, p < 0.05). This led to a significant increase in post-repolarization refractoriness (PRR, +32 ms, p < 0.01) as compared with sole ouabain treatment.Under baseline conditions, ventricular fibrillation (VF) was inducible by a standardized pacing protocol including programmed stimulation and burst stimulation in four of 13 hearts (31%; 15 episodes). After application of 0.2 lM ouabain, eight of 13 hearts were inducible (62%, 49 episodes). Additional infusion of 5 lM ivabradine led to a significant suppression of VF. Only four episodes could be induced in two of 13 hearts (15%).In this study, ivabradine reduced digitalis-induced ventricular arrhythmias. Ivabradine did not affect ventricular repolarization in the presence of digitalis treatment but demonstrated potent anti-arrhythmic properties based on an increase in both ERP and PRR. The study further characterizes the beneficial electrophysiological profile of ivabradine.
Digitalis glycosides selectively inhibit the cardiac Na + /K + -ATPase and thereby increase the intracellular sodium concentration. This results in a reduced extrusion of calcium as well as in an increase in calcium influx mediated by the Na+/Ca 2+ -exchanger (NCX). In combination with an augmentation of the calcium load of the sarcoplasmic reticulum, these mechanisms contribute to a positive inotropic effect explaining the history of digitalis glycosides for treatment of heart failure [1, 2] . However, the increase in intracellular calcium levels by digitalis glycosides also enhances pro-arrhythmic side effects. Negative effects on clinical outcome including an increased mortality have been reported years ago in patients with chronic heart failure [3] . A potential pro-arrhythmic effect of digitalis glycosides is attributed to a transient activation of depolarizing inward currents which induce delayed after-depolarizations and thereby enhance the occurrence of ventricular arrhythmias [2] . Of note, recent experimental [4, 5] and clinical evidence [6] suggests pro-arrhythmic effects of the combination of digitalis glycosides and the anti-arrhythmic agent dronedarone. Ivabradine mainly inhibits the pacemaker current I (f) and is clinically established for reduction in heart rate in patients with chronic heart failure [7] . Of note, no negative inotropic effects have been reported [7] .
In addition to the inhibition of the funny current, ivabradine also inhibits human ether-a-go-go-related-gene (hERG)-mediated potassium currents leading to a prolongation of ventricular repolarization [8, 9] . Of note, these effects were observed at concentrations between 2 lM and 4 lM [8] . In addition, ivabradine slows atrioventricular conduction in atrial fibrillation [10] [11] [12] [13] . The described electrophysiological profile of ivabradine suggests anti-arrhythmic properties in digitalisinduced ventricular arrhythmias.
The aim of this study was to investigate potential antiarrhythmic effects of ivabradine in an experimental model.
Methods
All experimental protocols were approved by the local animal care committee (LANUV NRW, Germany, permission no. 84-20.05.50.16.004) and conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 852-3, revised 1996).
The method of preparing and isolating the hearts using a Langendorff set-up has been described before [14] . The atrioventricular (AV) node was mechanically ablated employing surgical tweezers resulting in a complete atrioventricular dissociation. Seven specifically designed catheters for recording of monophasic action potentials (MAP) were positioned around both ventricles while one MAP was recorded from the left ventricular endocardium. Hearts were paced at pre-defined cycle lengths (CL).
Cycle length (CL) dependence of action potential duration was examined under baseline conditions. Action potential duration (APD 90 ) was measured as the interval between the fastest MAP upstroke and 90% repolarization. Spatial dispersion of repolarization Author for correspondence: Gerrit Frommeyer, Abteilung f€ ur Rhythmologie, Division of Electrophysiology, Department of Cardiovascular Medicine, University Hospital of M€ unster, Albert-Schweitzer Campus 1, 48149 M€ unster, Germany (e-mail gerrit.frommeyer@ukmuenster.de).
was assessed between left and right ventricles (interventricular) and between epicardial and endocardial sites of the left ventricle (intraventricular). Ventricular effective refractory period (ERP) was determined by programmed ventricular stimulation. Post-repolarization refractoriness (PRR) was defined as the difference of ERP and APD 90 [15] . Ventricular arrhythmias were induced by a standardized pacing protocol including programmed ventricular stimulation with one and two extra stimuli at different cycle lengths and aggressive burst stimulation (50 Hz). Then, ouabain (0.2 lM) was infused for 20 min. and measurements were repeated. Subsequently, ivabradine (5 lM) was administered in the presence of continuous ouabain infusion and the same measurements were performed. The dosage was derived from previous experimental studies where similar concentrations of ivabradine exerted inhibiting effects on hERG-mediated potassium currents [8] .
Drug effects on cycle length dependence of QT interval, APD and refractory periods were assessed using general linear model for repeated measures. The chi-squared test and the Fisher's test were used to compare the incidences of polymorphic VT. Differences are considered significant at p < 0.05.
Results
Effects of ouabain and ivabradine on QT interval, action potential.
Duration, spatial dispersion of repolarization and effective refractory periods. Infusion of ouabain led to a dosedependent decrease in APD 90 (156 AE 18 ms versus 129 AE 22 ms, mean over all cycle lengths and recording sites, p < 0.01; fig. 1 ). This marked reduction in APD 90 has been accompanied by a similar reduction in QT interval (baseline: 242 AE 27 ms versus 208 AE 27 ms, p < 0.01; fig. 1 ). In accordance, ouabain treatment resulted in a significant decrease in ERP (163 AE 20 ms versus 136 AE 14 ms, p < 0.01).
Of note, additional perfusion with ivabradine (5 lM) did not significantly alter the QT interval (208 AE 27 ms versus 204 AE 27 ms, p = 0.71) and APD 90 (129 AE 22 ms versus 114 AE 21 ms, p = 0.09) but significantly increased ERP (136 AE 14 ms versus 152 AE 16 ms, p < 0.05). This resulted in a remarkable and significant increase in PRR (7 AE 2 ms versus 39 AE 11 ms, p < 0.01) as compared with sole infusion of ouabain ( fig. 2) .
Total spatial dispersion of repolarization was not significantly altered by infusion of either ouabain or additional infusion of ivabradine (baseline: 48 AE 17 ms; ouabain: 54 AE 13 ms, p = 0.32; ivabradine: 47 AE 15 ms, p = 0.22).
Induction of ventricular arrhythmias. Before drug infusion, ventricular fibrillation was inducible by programmed ventricular stimulation and burst stimulation in four of 13 hearts (31%, 15 episodes). Acute treatment with ouabain led to an increased inducibility of ventricular fibrillation as compared with baseline eight of 13 hearts (62%, 49 episodes, fig. 3 ). After additional infusion of 5 lM ivabradine, only two of 13 hearts presented ventricular fibrillation (15%, four episodes). A representative example of ventricular fibrillation induced by programmed ventricular stimulation is displayed in fig. 4 .
Discussion
In the present study, an anti-arrhythmic effect of ivabradine in digitalis-induced ventricular arrhythmias was observed. The inducibility of ventricular fibrillation (VF) by programmed ventricular stimulation and aggressive burst stimulation was significantly increased by infusion of ouabain as compared with baseline data. The increased ventricular vulnerability observed in this study was accompanied by a significant abbreviation of the repolarization period. This shortening was characterized by a reduction in both QT interval and APD 90 . In addition, ventricular ERP was also significantly affected. These effects explain the pro-arrhythmic potential of digitalis glycosides that is also observed in the clinical setting.
Additional infusion of ivabradine significantly augmented ventricular ERP but did not induce a relevant prolongation of action potential duration and QT interval. This resulted in a A marked prolongation of ventricular refractory period represents an important electrophysiological mechanism that explains the anti-arrhythmic efficacy of established antiarrhythmic drugs. An increase in refractory period has been reported for sodium channel inhibitors (class I anti-arrhythmic drugs) [16] , the class III anti-arrhythmic agents amiodarone [14] and dronedarone [17] but also for lately introduced drugs that mainly interact with the late sodium current such as ranolazine [18] or vernakalant [19] [20] [21] .
The anti-arrhythmic effect of an increase in ventricular ERP and PRR is based on a prevention of premature excitation and thereby precludes origination of arrhythmias. The anti-arrhythmic potential of drug-induced increase in PRR was initially described for the sodium channel inhibitors procainamide and propafenone in isolated rabbit hearts. In accordance, experimental studies have reported the importance of an increased refractory period for the inhibition of the induction of ventricular tachyarrhythmias in a model of short QT syndrome. In this entity, treatment with quinidine [16] or the late sodium current inhibitors ranolazine or vernakalant [19] effectively inhibited induction of VF by a prolongation of refractory periods.
Similarly, in the present study, ivabradine induced a significant increase in PRR as a result of a more marked increase in ERP as compared with action potential duration. Previous experimental studies in different set-ups have already underlined that ivabradine affects ventricular repolarization in comparable dose ranges as employed in this investigation [8] . The electrophysiological effects of ivabradine can be explained by combined effects on I (f) as well as on hERG-mediated potassium currents [8] . In particular, inhibitory effects on the component I Kr explain the anti-arrhythmic properties in digitalisinduced arrhythmias.
Clinical implication.
Digitalis-induced ventricular arrhythmias can be regarded as rare but potentially life-threatening incidents. In particular, patients with underlying structural heart disease who may, for example, receive digitalis therapy for atrial fibrillation with rapid AV conduction are exposed to an increased risk of pro-arrhythmic events. In addition to the above-cited antiarrhythmic properties of ivabradine, previous studies also reported relevant effects for rate control in atrial fibrillation. An inhibitory effect on atrioventricular conduction in atrial fibrillation was initially described in an experimental study employing anaesthetized pigs and guinea pig hearts [10] . This effect was primarily attributed to the functional expression of I (f) channels in the atrioventricular node. Similar results were obtained in the same model for the combination of ranolazine and ivabradine [11] . Here, even additive effects of a combined administration of both agents were reported. Of note, these experimental results were confirmed in the clinical setting. In a small clinical trial, ivabradine significantly reduced heart rate compared to placebo in patients with non-paroxysmal atrial fibrillation [13] . In accordance, similar effects were described in case series [12] and case reports [22] . These effects on heart rate in combination with the anti-arrhythmic properties observed in the present study may enlarge the potential field of application of ivabradine in the clinical setting.
Limitations.
This study was conducted in an isolated rabbit whole-heart model. Therefore, certain differences to the clinical setting apply. The results of the present study cannot be directly translated to patients with paroxysmal AF because the induction of an AV block represents an important pathophysiological difference. However, an AV block is necessary to ensure standardized measurements of electrophysiological parameters in this model.
The employed ivabradine dose of 5 lM was derived from previously published experimental studies including patchclamp experiments [8] and whole-heart experiments [23] where distinct anti-arrhythmic effects including inhibition of hERG-mediated potassium currents were described. However, these dose ranges significantly exceed the currently established concentrations for heart rate reduction in chronic heart failure at which a predominant inhibition of the I (f) current is achieved [24] . 
Conclusion
Ivabradine effectively suppressed digitalis-induced arrhythmias in an experimental whole-heart model by reversing the abbreviation of ventricular refractory periods induced by the digitalis glycoside ouabain. These results suggest that ivabradine might also be considered for anti-arrhythmic drug therapy and in particular for prevention of digitalis-induced arrhythmias. Further clinical investigations are necessary to precisely characterize the effects of ivabradine in combination with digitalis glycosides.
